CN108567995A - 一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 - Google Patents
一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 Download PDFInfo
- Publication number
- CN108567995A CN108567995A CN201710144019.7A CN201710144019A CN108567995A CN 108567995 A CN108567995 A CN 108567995A CN 201710144019 A CN201710144019 A CN 201710144019A CN 108567995 A CN108567995 A CN 108567995A
- Authority
- CN
- China
- Prior art keywords
- cell
- culture
- epithelial cell
- buccal mucosa
- cell piece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims description 8
- 208000021921 corneal disease Diseases 0.000 title claims description 4
- 210000000321 buccal mucosa cell Anatomy 0.000 claims abstract description 24
- 210000000214 mouth Anatomy 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 208000005207 oral submucous fibrosis Diseases 0.000 claims abstract description 13
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 238000004113 cell culture Methods 0.000 claims abstract description 9
- 238000003501 co-culture Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 80
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 18
- 210000002950 fibroblast Anatomy 0.000 claims description 17
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 210000002808 connective tissue Anatomy 0.000 claims description 9
- 108010073385 Fibrin Proteins 0.000 claims description 8
- 102000009123 Fibrin Human genes 0.000 claims description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 8
- 229950003499 fibrin Drugs 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 229960004857 mitomycin Drugs 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 claims description 6
- 229940012952 fibrinogen Drugs 0.000 claims description 6
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 238000012549 training Methods 0.000 claims description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000004026 insulin derivative Substances 0.000 claims description 3
- 239000011435 rock Substances 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 235000019419 proteases Nutrition 0.000 claims description 2
- 230000008470 skin growth Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 239000010410 layer Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000004087 cornea Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000003328 fibroblastic effect Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102100028629 Cytoskeleton-associated protein 4 Human genes 0.000 description 3
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 210000001691 amnion Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 229940116978 human epidermal growth factor Drugs 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- -1 polyethylene terephthalate Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 239000004819 Drying adhesive Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 101710132662 Protein K3 Proteins 0.000 description 1
- 241000521327 Streptomyces caespitosus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GCNLQHANGFOQKY-UHFFFAOYSA-N [C+4].[O-2].[O-2].[Ti+4] Chemical compound [C+4].[O-2].[O-2].[Ti+4] GCNLQHANGFOQKY-UHFFFAOYSA-N 0.000 description 1
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
- A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0632—Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/097—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells oral mucosa cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及组织工程口腔黏膜上皮细胞片的制备方法。具体地,本发明提供一种口腔黏膜上皮细胞片的制备方法,包括以下步骤:(a)口腔黏膜组织采集步骤;(b)口腔黏膜上皮细胞提取步骤;(c)口腔黏膜成纤维细胞提取步骤;(d)上皮细胞培养基质和培养支架制备步骤;(e)口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养步骤;以及(f)制备得到的上皮细胞片与同培养材料的分离步骤。
Description
技术领域
本发明涉及组织工程与生物制品领域,具体地,本发明涉及一种用于角膜疾病(尤其是角膜眼表疾病)治疗的上皮细胞片的制备方法及其应用。
背景技术
人的眼角膜共分5层,由前向后依次为:上皮细胞层、前弹力层、基质层、后弹力层和内皮细胞层。上皮细胞层是最外面的一层,厚度约为50微米,占整个角膜厚度的10%,由5-6层细胞所组成。角膜周边部上皮增厚,细胞层数增加到8-10层。角膜上皮共有3种类型的细胞:基底细胞、翼状细胞、扁平细胞。上皮细胞间以桥小体相接,构成致密的质膜,这层致密坚固的屏障可阻止大部分微生物的侵入,阻止泪液中液体和电解质进入基质层,使得角膜处于相对脱水状态。由于外界原因和/或自身原因角膜上皮层会发生各种损伤和/或病变,情况严重导致失明。
化学伤、热灼伤或其他疾病(例如,Steven-Johnson、眼天疱疮等)可导致眼表损伤,破坏角膜上皮的结构和功能。目前,目前临床治疗主要依赖于异体角膜移植,但供体材料来源有限等困难严重制约了这一治疗方法的应用。而且,异体角膜移植仍然存在术后免疫反应,甚至出现供体排斥而致手术失败。
此外,现有治疗方法还包括人工角膜移植。目前,已有多种人工角膜应用于临床,但其材料均达不到理想要求。而且,由于人工角膜的晚期并发症:角膜溶解、植入物排出、房水渗漏、眼内炎、人工角膜后增生膜、青光眼等,目前仅适用于常规角膜移植失败的双眼角膜混浊性失明患者,一般只作为最后的选择。
还可采用的另一种治疗方法是:羊膜移植。人羊膜可作为基底膜、促进上皮细胞增殖和分化以及抗炎症抗粘连等用于眼表疾病的治疗,但羊膜是来源于异体组织,难免会带来供体的相关物质,其安全性值得考虑。
最近新起的一种治疗方法是:生物角膜移植,生物角膜虽然可以解决供体紧张及人工角膜缺陷的一些问题,但其来源是异种属,难以避免排异反应,其安全性值得考虑。
随着组织特异性干细胞知识的不断深入以及组织工程技术的飞速发展,自体角膜缘干细胞体外培养形成细胞片,用于眼表损伤的重建取得令人满意的临床效果。但是对于双眼眼表损伤的患者,因没有健康的角膜缘组织可供取材,故无法开展。
因此,本领域迫切需要一种更佳的角膜损伤治疗方法,既能解决供体不足的问题,同时也能避免异体移植可能发生的排斥反应以及长时间使用糖皮质激素和免疫抑制剂带来的一系列不良反应,从而为LSCD患者提供了个体化可行性治疗方案。
发明内容
在本发明的一方面,提供了一种口腔黏膜上皮细胞片的制备方法,包括以下步骤:
(a)口腔黏膜组织采集步骤;
(b)口腔黏膜上皮细胞提取步骤;
(c)口腔黏膜成纤维细胞提取步骤;
(d)上皮细胞培养基质和培养支架制备步骤;
(e)口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养步骤;以及
(f)制备得到的上皮细胞片与同培养材料的分离步骤。
在本发明一些优选的实施方式中,所述步骤(b)中口腔黏膜上皮细胞采用Ⅰ型中性蛋白酶联合胰蛋白酶进行消化。
在本发明一些优选的实施方式中,所述步骤(c)中口腔黏膜成纤维细胞采用经Ⅰ型中性蛋白酶消化后的结缔组织块贴附培养法培养提取。
在本发明一些优选的实施方式中,所述步骤(d)中的上皮细胞培养基质包含1IU/ml的凝血酶以及1-1.6mg/ml的纤维蛋白原。在一些具体的实施方式中,所述培养基质采用本发明所述包含表皮生长因子、胰岛素、Rock抑制剂的DMEM/F12培养基的进行配制。
在本发明一些优选的实施方式中,所述步骤(d)中的培养支架是外径约为23毫米、内径约为18毫米的O型圈。在一些实施方式中,本发明采用的培养基支架的外经为20-28毫米。在一些实施方式中,本发明采用的培养支架的内径为15-20毫米。在本发明一些优选的实施方式中,所述圈形培养支架的外径为23毫米,内径为18毫米,具有0.4微米的孔径和10微米的厚度。
在本发明一些优选的实施方式中,所述步骤(e)中口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养之前,口腔黏膜成纤维细胞采用丝裂霉素C进行处理。
在本发明一些优选的实施方式中,所述步骤(e)中口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养采用的培养基包含表皮生长因子、胰岛素、Rock抑制剂的DMEM/F12培养基。在本发明一些更优选的实施方式中,所述培养基是包含20纳克/毫升的重组人表皮生长因子、10微克/毫升重组人胰岛素、10微摩尔的Rock抑制剂Y-27632的DMEM/F12培养基。
在本发明的另一方面,提供了一种上皮细胞片,该上皮细胞片是采用本发明所述方法制备得到的。在一些优选的实施方式中,所述上皮细胞片是复层结构。
在本发明的另一方面,提供了一种本发明方法制备得到的上皮细胞片的用途。在一个具体的实施方式中,本发明方法制备得到的上皮细胞片用于制备适合角膜移植的移植物。
附图说明
图1显示了口腔上皮细胞片的制备工艺流程。
图2显示了口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养中使用的细胞培养支架的一个实施方式。
图3显示了培养的口腔黏膜上皮细胞片组织学切片HE染色结果。
图4A-4C分别显示了第2天、第4天和第6天观察到成纤维细胞的显微镜图片(放大倍数4x)。
图5A和5B分别显示了经丝裂霉素C处理的成纤维细胞在显微镜下的形态以及培养24小时后可以作为饲养细胞与口腔上皮细胞共培养的成纤维细胞的形态。
图6显示上皮细胞融合达到80%的结果。
图7显示细胞融合达到100%的结果。
图8A-8B显示p63蛋白和K3蛋白有明显表达阳性的图片。
具体实施方式
发明人经过广泛而深入的研究,发现利用组织工程共培养获得的自体口腔黏膜上皮细胞片能够用于角膜移植,具有良好的修复效果。本发明用自体口腔成纤维细胞为共培养的饲养细胞,代替了国际普遍使用的鼠源饲养细胞,使培养后的口腔黏膜上皮片更安全,并解决了细胞培养共培养中的所用动物来源饲养细胞难题。
上皮细胞
通过自体口腔上皮细胞-自体口腔成纤维细胞共培养经过上皮细胞原代扩增培养、上皮细胞继代增殖分化培养所制造的细胞片为多种形态上皮细胞的复层细胞结构,其中包含表达干细胞特性P63蛋白的上皮基质细胞、K3蛋白特性的分化的上皮角质细胞。
自体口腔黏膜上皮细胞片组织为复层细胞片,包括角质细胞层,基质细胞层,因此具有增殖和分化功能。
本发明所述方法制备的细胞片的特点是,上皮细胞和共培养的成纤维细胞来源均来自于患者自体,用于组织工程产品临床治疗减少排斥反应,大大提高术后恢复效果。
成纤维细胞
成纤维细胞提取用经Ⅰ型中性蛋白酶消化后的结缔组织块贴附培养法培养提取,成纤维细胞培养使用基础培养基为DMEM(Hyclone Cat:SH30243.01B)。
成纤维细胞作为共培养饲养细胞处理。利用丝裂霉素C对DNA增殖和聚合有抑制作用,阻断成纤维细胞增殖从而分泌表达大量蛋白类生长因子为共培养的上皮细胞提供营养。
尽管自体的成纤维细胞是优选的,但异体的成纤维细胞的来源也可使用。
培养支架
本发明的培养支架采用O型圈状结构,构成支架的材料是聚对苯二甲酸乙二醇酯(PET)。
当然,本发明的培养支架也可以采用其他采用材料制成。
可用于制备本发明的培养支架的材料是医学上可接受的聚合物材料,包括(但并不限于):
(a)可降解性合成高分子材料,例如聚α-羟基酸(如聚乳酸PLA、聚羟基乙酸PGA、聚羟基丁酸PHB等)、聚酸酐、聚偶磷氮、聚氨基酸、假聚氨基酸、聚原酸酯、聚酯尿烷、聚碳酸酯、聚乙二醇、聚环氧乙烷、聚对二氧六环酮等;
(b)天然可降解材料,例如胶原、明胶、糖氨聚糖、壳聚糖、甲壳素、海藻酸盐、藻酸钙凝胶等;各种脱细胞基质;
(c)上述材料的混合物或复合材料,尤其是高分子材料与天然材料的复合材料。
本发明中采用的这种O型圈状培养支架具有0.4微米孔径和10微米的厚度,外圈直径为23毫米、内部直径为18毫米。这种O型圈状培养支架的形状、大小刚好符合通用培养六孔培养板Transwell小室(康宁目录号:3450)的大小。而且,培养出的上皮细胞片大小能完全覆盖人眼角膜整个表面利于手术操作。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,例如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring HarborLaboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。
实施例中采用的主要试剂来源如下表1所示。
表1
| 名称 | 厂家 | 货号 |
| 重组人表皮生长因子 | Gibco | PHG0313 |
| 重组人胰岛素 | Prospec | CYT‐270 |
| Y-27632 | Selleck | S104910 |
| IV型胶原蛋白 | Sigma | C5533‐5MG |
实施例1:口腔黏膜上皮细胞的提取与冻存
受试者在使用漱口水一周后取材,取材在无菌手术室进行。取材时先对患者本人的口腔用碘伏进行表面消毒,局麻下用眼科手术专用器械8毫米的环转在左右两侧口腔各取一块2mm厚度(含上皮层和结缔组织层)的健康圆形口腔黏膜组织,取好的口腔黏膜组织立即放入含有青霉素/链霉素双抗的DMEM/F12(1:1,Hyclone Cat:SH30271.01)培养液中,完成受试者口腔黏膜的采集。注意:手术中所用所有器械全部无菌。
在无菌实验室生物安全柜内,将口腔黏膜组织倒入培养皿,用无菌镊子把组织转移到含PBS的培养皿中清洗一遍,去除血液和其他可能杂质。在体式显微镜下用无菌剪刀剪成2x 2毫米的小块,把剪好的组织块用无菌镊子转移到新的培养皿中,加入600单位/毫升的I型中性蛋白酶,37度,摇床80转/分钟,反应1小时。显微镜下,用镊子分离上皮层组织和结缔组织部分,浅黄色为上皮层组织、白色为结缔组织,且分离后连接面明显可见锯齿形状。
上皮层组织用无菌镊子转入新的培养皿,用0.05%胰蛋白酶-乙二胺四乙酸溶液在室温下消化反应7分钟。反应结束吸去胰蛋白酶-乙二胺四乙酸溶液,加入含有10%胎牛血清的DMEM培养液终止胰蛋白酶消化作用。在显微镜下用镊子轻轻敲打上皮组织,释放出上皮细胞。
收集上皮细胞悬液到离心管中,1000转/分钟,离心5分钟。去除离心上清后,加入新鲜培养基重悬细胞,并进行台盼蓝染色细胞计数。细胞悬液再次离心去除上清,根据细胞计数得到的活细胞数,按1x106个/ml的细胞浓度加入细胞冻存液(DMEM+10%胎牛血清+10%二甲基亚砜)。按照200-500微升/支进行分装到细胞冻存管中,按4度放1-4小时后到零下80度过夜再到零下196度液氮降温顺序冻存细胞长期保存备用。
实施例2:口腔黏膜成纤维细胞的提取与培养
将口腔黏膜上皮细胞提取过程中的经I型中性蛋白酶消化反应后分离的结缔组织转入装有新鲜DMEM+10%胎牛血清培养基的培养皿中。在体式显微镜下用剪刀剪成1x 1毫米大小的小块,把剪好的小块结缔组织用无菌镊子取出均匀排列在新的直径60毫米培养皿中,不加培养液,37度放置2-3小时使其完全贴附在培养皿底部。待结缔组织完全贴壁后加入新鲜DMEM+10%胎牛血清培养基5毫升,37度,5%二氧化碳培养;每天显微镜下观察是否有细胞爬出生长,隔天换液。
图4A-4C分别显示了第2天、第4天和第6天观察到成纤维细胞的显微镜图片(放大倍数4x)。
实施例3:口腔黏膜上皮细胞与口腔黏膜成纤维细胞的共培养
当实施例2制备的成纤维细胞生长细胞融合度达到90%以上,去除旧的培养液,加入含4微克/毫升丝裂霉素C的DMEM+10%胎牛血清培养基,37度孵育反应2小时。吸去旧的培养液,用PBS洗涤3次,0.25%胰蛋白酶-乙二胺四乙酸,37度,3分钟消化细胞,消化后用含DMEM+10%胎牛血清培养基终止消化。收集细胞悬液,1000转/分钟,离心5分钟去除上清后加入新鲜DMEM+10%胎牛血清重悬细胞并进行台盼蓝染色细胞计数、接种,细胞接种密度:1.0-1.5x105个/孔(6孔板BD Falcon cat:353046)。37℃,5%二氧化碳培养,24小时后该成纤维细胞可以作为饲养细胞与口腔上皮细胞共培养。
该步骤中使用的丝裂霉素C是从头状链霉菌培养液中分离提取的一种广谱抗生素,其可使细胞的DNA解聚,同时阻碍DNA的复制,从而抑制细胞分裂。
图5A和5B分别显示了经丝裂霉素C处理的成纤维细胞在显微镜下的形态以及培养24小时后可以作为饲养细胞与口腔上皮细胞共培养的成纤维细胞的形态。
然后,将实施例1制备的口腔黏膜上皮细胞从液氮中取出,快速冻融加入预热的上皮细胞培养基(主要为:DMEM/F12含20纳克/毫升的重组人表皮生长因子、10微克/毫升重组人胰岛素、10微摩尔的Rock抑制剂Y-27632),1000转/分钟,5分钟离心后重悬细胞并进行台盼蓝染色细胞计数,根据活细胞数计算接种细胞。细胞接种密度:1.0-1.5x105/Transwell小室(康宁公司3450),接种用的Transwell小室使用前按1微克/平方厘米的IV型胶原蛋白溶液37度进行包被1小时。用于共培养丝裂霉素C处理后培养了24小时的成纤维细胞培养液完全更换成口腔上皮细胞培养基(主要为:DMEM/F12含20纳克/毫升的重组人表皮生长因子、10微克/毫升重组人胰岛素、10微摩尔的Rock抑制剂Y-27632),接种上皮细胞的Transwell小室放入更换培养基后的饲养成纤维细胞的细胞板中共培养,37度,5%二氧化碳进行共培养,上皮细胞扩增培养期间,每天显微镜下观察细胞生长状况,隔天换液。
该步骤中使用的Transwell小室为康宁公司的细胞培养用产品,其底部为0.4微米孔径厚度10微米的聚对苯二甲酸乙二醇脂(PET)材料,培养基和细胞分泌的各种物质能顺利通过,细胞不能通过被完全分开,该产品配套6孔板用于细胞共培养。
实施例4:上皮细胞片的制备
细胞片培养前先准备适用于口腔黏膜上皮细胞片的培养支架和培养基质。
培养支架:采用同Transwell小室底部一致的聚对苯二甲酸乙二醇酯(PET)、0.4μm孔径10μm厚度的材料,制成外圈直径为23mm、内部直径为18mm的圆环,灭菌包装袋封口包装,121℃,0.11MPa,30分钟湿热灭菌并55度烘干备用。
培养基质:使用外用冻干纤维蛋白粘合剂(购自上海莱士血液制品股份有限公司)制备本发明的培养基质(Fibrin)。外用冻干纤维蛋白粘合剂主要组成成分如下:本品是一个混合包装的外用冻干人纤维蛋白粘合剂,包装内含有冻干人纤维蛋白原,冻干人凝血酶二种血浆蛋白成分,并附有灭菌注射用水及氯化钙水溶液作为配制用稀释液,以及配制药液和使用产品所需的无菌医用材料。本发明的具体制备过程如下。首先,制备500IU/ml的凝血酶的保存液以及50-80毫克/毫升纤维蛋白原的保存液。然后,准备1.5ml离心管2支,编号A、B,分别加入上皮细胞扩增培养的培养基(DMEM/F12添加重组人表皮生长因子、重组人胰岛素、Rock抑制剂Y-27632),A管298.8微升、B管288微升;A管稀释凝血酶溶液,加入1.2微升凝血酶轻轻混合均匀、B管稀释纤维蛋白原,加入12微升纤维蛋白原溶液轻轻混合均匀,纤维蛋白原具有粘性,添加和混匀时应避免产生气泡;吸取B管纤维蛋白酶原稀释液快速加入到A管中混匀,避免产生气泡。最终总体积为600微升,凝血酶浓度为1IU/ml、纤维蛋白原浓度为1-1.6毫克/毫升。混匀的溶液快速加入到已放入培养支架O-型圈的Transwell小室(康宁目录号:3450)中,用镊子夹起Transwell小室轻轻晃动使液体均匀铺满底部后放入六孔板内,6孔板再放入37℃培养箱,1小时后观察其是否凝固,如完全凝固表面平整无气泡则合格待用。
当实施例3中上皮细胞细胞融合达到80%(图6)以上开始传代培养。细胞传代时先吸除旧的培养液,加入0.02%乙二胺四乙酸-PBS溶液、37度反应10分钟,再加入胰蛋白酶溶液终浓度:0.05%,37度反应5分钟,轻轻吹打使细胞完全悬浮后加入含10%胎牛血清的上皮细胞培养基(主要为:DMEM/F12含20纳克/毫升的重组人表皮生长因子、10微克/毫升重组人胰岛素、10微摩尔的Rock抑制剂Y-27632)终止胰蛋白酶消化作用。收集细胞悬液,1000转/分钟,5分钟离心后含10%胎牛血清和抑制Fibrin降解的抑肽酶的上皮细胞培养基重悬用细胞并进行台盼蓝染色细胞计数,根据活细胞数计算接种细胞量,上述实施例准备好的含培养支架和培养基质接种用的Transwell小室使用前按1微克/平方厘米的IV型胶原蛋白溶液37度进行包被1小时,接种密度1.5-2.0x 105/Transwell小室(康宁3450)。接种上皮细胞的Transwell小室放入已接种饲养成纤维细胞并培养24小时完全更换培养基的6孔细胞板中,37度,5%二氧化碳进行共培养,每天显微镜下观察细胞生长状况并换液。细胞融合达到100%(图7)后开始层叠化细胞分化培养,层叠化培养共进行3天。
细胞分化培养结束,在体式显微镜下分离细胞片同Transwell小室,轻轻揭起细胞片,揭起的上皮细胞片完整无孔洞、透明。
实施例5:上皮细胞片的生物学性能检测
细胞片生物性能检测包括活细胞数检测、细胞形态学检测、细胞功能蛋白表达检测。
活细胞数检测:台盼蓝染色活细胞计数。取培养好的上皮细胞片,平铺放在硅胶板上,硅胶板下放坐标纸,用刀片平均把细胞片切成两个半圆,一半用于活细胞计数、另一半用于形态学和功能蛋白表达检测。
切好的半片细胞片用0.02%乙二胺四乙酸-PBS溶液、37度反应10分钟,再加入胰蛋白酶溶液终浓度:0.05%,37度反应5分钟,轻轻吹打使细胞完全悬浮后加入含10%胎牛血清的上皮细胞培养基终止胰蛋白酶消化作用。收集细胞悬液,1000转/分钟,5分钟离心后重悬细胞并进行台盼蓝染色细胞计数,计算整个细胞片的活细胞总数和活细胞率,活细胞总数大于等于2x105个/片、活细胞率大于等于50%为合格。
形态学检测:细胞片组织切片“苏木精-伊红”染色。“9-1”中另一半细胞片用4%多聚甲醛固定后做组织切片,切片后“苏木精-伊红”染色,染色后可见多层(基质层形态和分化层形态)细胞,细胞层数大于等于2层为合格。
功能蛋白表达检测:细胞片组织切片免疫组化。“9-2”中细胞片组织切片进行免疫组化反应检测,选用基质细胞特异表达蛋白p63抗体和分化细胞特异表达蛋白K3抗体进行检测反应,结果p63蛋白和K3蛋白有明显表达阳性为合格(图8A、图8B)。
由此可见,采用本发明的方法制备得到的上皮细胞片,完整透明,细胞多层,细胞特性检测均符合组织工程细胞片质量要求。
受试者自体口腔黏膜上皮细胞片用于受试者自身眼表疾病的眼表覆盖手术治疗,对眼表外观、视力有显著疗效。
以上的实施例是为了说明本发明公开的实施方案,并不能理解为对本发明的限制。此外,本文所列出的各种修改以及发明中方法、组合物的变化,在不脱离本发明的范围和精神的前提下对本领域内的技术人员来说是显而易见的。虽然已结合本发明的多种具体优选实施例对本发明进行了具体的描述,但应当理解,本发明不应仅限于这些具体实施例。事实上,各种如上所述的对本领域内的技术人员来说显而易见的修改来获取发明都应包括在本发明的范围内。
Claims (10)
1.一种用于角膜疾病治疗的上皮细胞片的制备方法,包括以下步骤:
(a)口腔黏膜组织采集步骤;
(b)口腔黏膜上皮细胞提取步骤;
(c)口腔黏膜成纤维细胞提取步骤;
(d)上皮细胞培养基质和培养支架制备步骤;
(e)口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养步骤;以及
(f)制备得到的上皮细胞片与同培养材料的分离步骤。
2.如权利要求1所述的方法,其特征在于,所述步骤(b)中口腔黏膜上皮细胞采用Ⅰ型中性蛋白酶联合胰蛋白酶进行消化。
3.如权利要求1所述的方法,其特征在于,所述步骤(c)中口腔黏膜成纤维细胞采用经Ⅰ型中性蛋白酶消化后的结缔组织块贴附培养法培养提取。
4.如权利要求1所述的方法,其特征在于,所述步骤(d)中的上皮细胞培养基质包含1IU/ml的凝血酶以及1-1.6mg/ml的纤维蛋白原。
5.如权利要求1所述的方法,其特征在于,所述步骤(d)中的培养支架是外径为23毫米、内径为18毫米的O型圈。
6.如权利要求1所述的方法,其特征在于,所述步骤(e)中口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养之前,口腔黏膜成纤维细胞采用丝裂霉素C进行处理。
7.如权利要求1所述的方法,其特征在于,所述步骤(e)中口腔黏膜上皮细胞与口腔黏膜成纤维细胞共培养采用的培养基包含表皮生长因子、胰岛素、Rock抑制剂的DMEM/F12培养基。
8.如权利要求7所述的方法,其特征在于,所述培养基是包含20纳克/毫升的重组人表皮生长因子、10微克/毫升重组人胰岛素、10微摩尔的Rock抑制剂Y-27632的DMEM/F12培养基。
9.如权利要求1所述的方法制备得到的上皮细胞片,所述细胞片为复层结构。
10.如权利要求9所述的上皮细胞片的用途,用于制备用于角膜移植的移植物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710144019.7A CN108567995A (zh) | 2017-03-10 | 2017-03-10 | 一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710144019.7A CN108567995A (zh) | 2017-03-10 | 2017-03-10 | 一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108567995A true CN108567995A (zh) | 2018-09-25 |
Family
ID=63578041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710144019.7A Pending CN108567995A (zh) | 2017-03-10 | 2017-03-10 | 一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108567995A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119752775A (zh) * | 2025-03-03 | 2025-04-04 | 上海尚瑞生物医药科技有限公司 | 一种无损地将培养中的细胞片从培养容器的细胞培养面揭离的方法 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589126A (zh) * | 2001-11-19 | 2005-03-02 | 阿姆尼奥泰克股份有限公司 | 角膜上皮样片材及其制造方法 |
| CN1747753A (zh) * | 2003-02-06 | 2006-03-15 | 赛尔斯德株式会社 | 用于形成角膜上皮的细胞片、及其制造方法和使用方法 |
| CN1929877A (zh) * | 2004-03-11 | 2007-03-14 | 阿如布勒斯特有限公司 | 角膜上皮片及其制作方法、以及使用该片的移植方法 |
| CN101014375A (zh) * | 2004-06-30 | 2007-08-08 | 阿如布勒斯特有限公司 | 角膜上皮片及其制作方法 |
| CN101444645A (zh) * | 2007-11-28 | 2009-06-03 | 上海交通大学医学院附属第九人民医院 | 一种构建粘膜移植物的方法 |
| CN102787094A (zh) * | 2011-05-17 | 2012-11-21 | 李晖 | 培养基、细胞培养用试剂盒及细胞培养方法 |
| CN103031270A (zh) * | 2013-01-05 | 2013-04-10 | 绍兴文理学院 | 胆管上皮细胞的高效扩增和培养方法 |
| CN105176914A (zh) * | 2015-10-13 | 2015-12-23 | 怡诺博(北京)生物医学技术有限公司 | 自体表皮细胞和成纤维细胞同时制备方法及其生物美容产品 |
| CN105308175A (zh) * | 2013-03-11 | 2016-02-03 | 日本化学研究株式会社 | 人角膜上皮片的制造法 |
-
2017
- 2017-03-10 CN CN201710144019.7A patent/CN108567995A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589126A (zh) * | 2001-11-19 | 2005-03-02 | 阿姆尼奥泰克股份有限公司 | 角膜上皮样片材及其制造方法 |
| CN1747753A (zh) * | 2003-02-06 | 2006-03-15 | 赛尔斯德株式会社 | 用于形成角膜上皮的细胞片、及其制造方法和使用方法 |
| CN1929877A (zh) * | 2004-03-11 | 2007-03-14 | 阿如布勒斯特有限公司 | 角膜上皮片及其制作方法、以及使用该片的移植方法 |
| CN101014375A (zh) * | 2004-06-30 | 2007-08-08 | 阿如布勒斯特有限公司 | 角膜上皮片及其制作方法 |
| CN101444645A (zh) * | 2007-11-28 | 2009-06-03 | 上海交通大学医学院附属第九人民医院 | 一种构建粘膜移植物的方法 |
| CN102787094A (zh) * | 2011-05-17 | 2012-11-21 | 李晖 | 培养基、细胞培养用试剂盒及细胞培养方法 |
| CN103031270A (zh) * | 2013-01-05 | 2013-04-10 | 绍兴文理学院 | 胆管上皮细胞的高效扩增和培养方法 |
| CN105308175A (zh) * | 2013-03-11 | 2016-02-03 | 日本化学研究株式会社 | 人角膜上皮片的制造法 |
| CN105176914A (zh) * | 2015-10-13 | 2015-12-23 | 怡诺博(北京)生物医学技术有限公司 | 自体表皮细胞和成纤维细胞同时制备方法及其生物美容产品 |
Non-Patent Citations (3)
| Title |
|---|
| T NAKAMURA ET AL: "Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders", 《BRITISH JOURNAL OF OPHTHALMOLOGY》 * |
| 张敏等: "角膜上皮细胞体外培养的研究进展", 《中国中医眼科杂志》 * |
| 牟式鲁: "以自体结膜成纤维细胞为饲养细胞构建组织工程兔角膜上皮", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119752775A (zh) * | 2025-03-03 | 2025-04-04 | 上海尚瑞生物医药科技有限公司 | 一种无损地将培养中的细胞片从培养容器的细胞培养面揭离的方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140220102A1 (en) | Ectocornea-like sheet and method of constructing the same | |
| Talbot et al. | Autologous transplantation of rabbit limbal epithelia cultured on fibrin gels for ocular surface reconstruction | |
| JP5946046B2 (ja) | ヒト角膜内皮細胞シート | |
| US20060153928A1 (en) | Aminion-origin medical material and method of preparing the same | |
| US20050214259A1 (en) | Corneal endothelium-like sheet and method of constructing the same | |
| US20080039940A1 (en) | Biological Tissue Sheet, Method Of Forming The Same And Transplantation Method By Using The Sheet | |
| JP5255846B2 (ja) | 生体内で細胞増殖可能な角膜内皮製剤 | |
| KR20070093991A (ko) | 양막을 이용한 시트형 조성물 및 그 제작 방법 | |
| NO334974B1 (no) | Keratinocyter, produkt, fremgangsmåte for frysekonservering av keratinocytter, samt anvendelse av keratinocytter | |
| JP2004024852A (ja) | 角膜内皮様シート、及びその作製方法 | |
| US20080026030A1 (en) | Corneal Epithelial Sheet and Process for Producing the Same | |
| CN108066750A (zh) | 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途 | |
| CN109679912A (zh) | 一种大鼠嗅鞘细胞的分离培养方法 | |
| CN108567995A (zh) | 一种用于角膜疾病治疗的上皮细胞片的制备方法及其应用 | |
| CN108570415A (zh) | 一种用于制备上皮细胞片的培养装置及其应用 | |
| WO2007043255A1 (ja) | 培養角膜内皮シート及びその作製方法 | |
| CN108939161B (zh) | 一种人源化活性去细胞角膜基质支架的制备方法 | |
| JP2009225675A (ja) | 上皮系細胞シートの作製のための同種皮膚由来フィーダー細胞 | |
| WO2007032224A1 (ja) | 培養細胞シート及びその作製方法 | |
| CN108578778A (zh) | 一种用于眼表损伤修复的细胞植片及其制备方法 | |
| CN108498863A (zh) | 一种复合口腔粘膜上皮细胞的口腔补片制备方法 | |
| CN108057131A (zh) | 一种含有干细胞的新型试剂盒 | |
| Huang | Corneal tissue engineering | |
| CN105326862A (zh) | 治疗烧伤皮肤的干细胞制剂及其制备方法 | |
| Giroux-Talbot et al. | Autologous transplantation of rabbit limbal epithelia cultured on fibrin gels for ocular surface reconstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210716 Address after: Room 201, building 2, No. 695, Lingshi Road, Jing'an District, Shanghai 200072 Applicant after: SHANGHAI REMED BIOTECHNOLOGY Co.,Ltd. Address before: 200072 Room 201, building 2, No. 695, Lingshi Road, Zhabei District, Shanghai Applicant before: SHANGHAI REMED BIOTECHNOLOGY Co.,Ltd. Applicant before: HEFEI XINRUI BIOTECHNOLOGY Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180925 |